Key Takeaway: Kiniksa Pharmaceuticals reported a strong financial performance for Q2 2026, with ARCALYST achieving net product revenues of $243.6 million, reflecting a 55% increase from the previous year. The company has raised its revenue expectations for ARCALYST to between $980 and $995 million for 2026. Additionally, Phase 2 data for KPL-387 demonstrated promising results in reducing pain and inflammation.
Price reaction · baseline $63.535 (2026-07-27 close) · hit pre-market · clean, no other KNSA news in the window
Expected net product revenue for ARCALYST is projected to increase.
KPL-387 Phase 2 data indicates effective pain and inflammation reduction.
Full Press Release Details
– ARCALYST ¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC
Frequently Asked Questions
What were Kiniksa's Q2 2026 net product revenues?
Kiniksa reported net product revenues of $243.6 million for Q2 2026.
How much is the expected revenue for ARCALYST in 2026?
The expected net product revenue for ARCALYST in 2026 is between $980 and $995 million.
What did KPL-387 Phase 2 data show?
KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation.
What is the year-over-year growth for ARCALYST?
ARCALYST achieved a year-over-year revenue growth of approximately 55%.